Skip to main content

Drug Interactions between aldesleukin and interferon alfa-2b / ribavirin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

interferon alfa-2b aldesleukin

Applies to: interferon alfa-2b / ribavirin and aldesleukin

MONITOR CLOSELY: The concomitant use of aldesleukin and interferon alfa may increase the risk of severe rhabdomyolysis and myocardial injury, including myocardial infarction, myocarditis and ventricular hypokinesia. In addition, the use of sequential high-dose aldesleukin and interferon alfa has been associated with hypersensitivity reactions requiring medical intervention. Symptoms occurred within a few hours after administration and included erythema, pruritus, and hypotension.

MANAGEMENT: Caution and close clinical and laboratory monitoring for signs and symptoms of toxicity and hypersensitivity reactions is advisable.

References (4)
  1. (2001) "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  3. Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
  4. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html

Drug and food interactions

Moderate

ribavirin food

Applies to: interferon alfa-2b / ribavirin

ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of ribavirin. Administration of a single oral dose of ribavirin following a high-fat meal delayed absorption (Tmax was doubled) but increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by up to 70% compared to administration in the fasting state.

MANAGEMENT: To ensure maximal oral absorption, ribavirin should be administered with or immediately after a meal.

References (2)
  1. (2003) "Product Information. Copegus (ribavirin)." Roche Laboratories
  2. (2004) "Product Information. Rebetol (ribavirin)." Schering-Plough Corporation

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer